Table 4.

Diagnostic performance of VI for luminal A, triple-negative, and HER-2-positive invasive breast cancers.

Molecular subtype	Cut point	Sensitivity (95% CI)	Specificity (95% CI)	PPV (95% CI)	NPV (95% CI)	ACC	AUC (95% CI)
Luminal A	4.1%	79.9% (73.4%~85.4%)	41.5% (26.3%~57.9%)	86.0% (82.4%~88.9%)	31.5% (22.4%~42.2%)	72.9%	0.58 (0.51~0.65)
Triple-negative	16.4%	30.0% (17.9%~44.1%)	90.3% (84.9%~94.24%)	46.9% (32.2%~62.1%)	81.9% (78.9%~84.5%)	76.9%	0.60 (0.53 ~ 0.67)
HER-2	5.3%	76.5% (50.1%~93.2%)	37.0% (30.4%~44.0%)	9.0% (7.0%~11.6%)	95.1% (88.9%~97.9%)	40.0%	0.55 (0.48~0.62)

HER-2, human epidermal growth factor receptor-2.